Impact of asymmetric stent expansion on neointimal hyperplasia following sirolimus-eluting stent implantation.
To assess whether asymmetric stent expansion affects suppression of neointimal hyperplasia after sirolimus-eluting stent implantation, 64 patients in the SIRolImUS-coated Bx Velocity stent trial who underwent single 18-mm stent implantation and 3-dimensional intravascular ultrasonography at 8-month follow-up were enrolled. To assess the longitudinal stent asymmetric expansion, 2 cross sections with a maximal/minimal stent area were chosen in each patient. To assess for tomographic stent asymmetric expansion, stent eccentricity was determined by dividing the minimum stent diameter by the maximum stent diameter. At the 2 cross sections with a maximal/minimal stent area, a sirolimus-eluting stent reduced neointimal hyperplasia significantly with no interaction between the treatment and stent areas. A sirolimus-eluting stent also significantly reduced neointimal hyperplasia in the concentric and eccentric stent groups.
Kaneda
Hideaki
H
Center for Research in Cardiovascular Interventions, Stanford University, Stanford, CA, USA.
Ako
Junya
J
Honda
Yasuhiro
Y
Terashima
Mitsuyasu
M
Morino
Yoshihiro
Y
Yock
Paul G
PG
Popma
Jeffrey J
JJ
Leon
Martin B
MB
Moses
Jeffrey W
JW
Fitzgerald
Peter J
PJ
D015906:Angioplasty, Balloon, Coronary; D019917:Blood Vessel Prosthesis Implantation; D020099:Coated Materials, Biocompatible / Q000627:therapeutic use*; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000628:therapy; D004311:Double-Blind Method; D005500:Follow-Up Studies; D006801:Humans; D006965:Hyperplasia / Q000000981:diagnostic imaging; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000000981:diagnostic imaging / Q000628:therapy; D011446:Prospective Studies; D020123:Sirolimus / Q000627:therapeutic use*; D015607:Stents; D016896:Treatment Outcome; D017539:Tunica Intima / Q000187:drug effects / Q000473:pathology* / Q000601:surgery; D018084:Ultrasonography, Interventional
D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D020123:Sirolimus